Study on the Factors Related to Cholesterol Metabolism Pathway and Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (non-alcoholic steatohepatitis is its serious subtype) has been the most common chronic liver disease in China, and its incidence is still increasing year by year. At present, the pathogenesis of nonalcoholic fatty liver disease is widely recognized as the “multi-hit theory”, and the “cholesterol metabolism” in this theory has also been concerned by many scho-lars. Therefore, in this paper, the pathogenesis of nonalcoholic fatty liver disease is described in combination with the relevant factors in the cholesterol metabolic pathway in recent years in or-der to provide a relevant reference for the clinical treatment and research of the disease.

[1]  F. Zhou,et al.  Cholesterol Metabolism: A Double-Edged Sword in Hepatocellular Carcinoma , 2021, Frontiers in Cell and Developmental Biology.

[2]  Chao-ke Tang,et al.  Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. , 2021, Progress in lipid research.

[3]  Min Hye Lee,et al.  ABCA1 69C>T Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Systematic Review and Updated Meta-Analysis , 2021, Frontiers in Endocrinology.

[4]  P. Malhotra,et al.  Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases , 2020, Frontiers in Medicine.

[5]  Toshihiro Kobayashi,et al.  Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes , 2020, Molecular metabolism.

[6]  G. Svegliati-Baroni,et al.  Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. , 2019, Free radical biology & medicine.

[7]  S. Ishibashi,et al.  Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice , 2019, Diabetes.

[8]  M. Saruta,et al.  Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma , 2019, Front. Oncol..

[9]  B. Jun,et al.  The utility of ezetimibe therapy in nonalcoholic fatty liver disease , 2019, The Korean journal of internal medicine.

[10]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[11]  R. DeBose-Boyd,et al.  Underlying mechanisms for sterol-induced ubiquitination and ER-associated degradation of HMG CoA reductase. , 2018, Seminars in cell & developmental biology.

[12]  J. P. Castro,et al.  Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol , 2018, Nutrients.

[13]  J. Goldstein,et al.  Retrospective on Cholesterol Homeostasis: The Central Role of Scap. , 2018, Annual review of biochemistry.

[14]  P. Malhotra,et al.  Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis. , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[15]  Xiaobo Li,et al.  Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[16]  Jin Ren,et al.  Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis , 2017, Acta Pharmacologica Sinica.

[17]  C. Aguilar-Salinas,et al.  Hepatic miR‐33a/miR‐144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[18]  M. Moghadasian,et al.  The Role of Dietary Cholesterol in Lipoprotein Metabolism and Related Metabolic Abnormalities: A Mini-review , 2016, Critical reviews in food science and nutrition.

[19]  R. Dalle Grave,et al.  Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice , 2015, Hepatology.

[20]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[21]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[22]  Mingshi Yang,et al.  miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. , 2015, International journal of molecular medicine.

[23]  N. Davidson,et al.  Cholesterol and nonalcoholic fatty liver disease: Renewed focus on an old villain , 2012, Hepatology.

[24]  V. Pallottini,et al.  Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station". , 2012, World journal of hepatology.

[25]  A. Sanyal,et al.  Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. , 2012, Cell metabolism.

[26]  M. Nakamuta,et al.  Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol , 2012, International journal of hepatology.

[27]  T. Saibara,et al.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study , 2012, Journal of Gastroenterology.

[28]  M. Yeh,et al.  Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. , 2011, Gastroenterology.

[29]  G. Farrell,et al.  SREBP‐2: A link between insulin resistance, hepatic cholesterol, and inflammation in NASH , 2011, Journal of gastroenterology and hepatology.

[30]  Z. Varghese,et al.  Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis , 2011, Journal of gastroenterology and hepatology.

[31]  H. Aburatani,et al.  Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. , 2011, Metabolism: clinical and experimental.

[32]  C. Dejong,et al.  Dietary cholesterol, female gender and n-3 fatty acid deficiency are more important factors in the development of non-alcoholic fatty liver disease than the saturation index of the fat , 2011, Nutrition & metabolism.

[33]  A. Feldstein,et al.  Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal , 2009, Expert review of gastroenterology & hepatology.

[34]  G. Ioannou,et al.  Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population , 2009, Hepatology.

[35]  Y. Maehara,et al.  Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. , 2009, International journal of molecular medicine.

[36]  F. Sladek,et al.  Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs. , 2009, Molecular endocrinology.

[37]  M. Nakashima,et al.  Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterol , 2009, Scandinavian journal of gastroenterology.

[38]  Puneet Puri,et al.  Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression , 2008, Hepatology.

[39]  A. Colell,et al.  Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. , 2006, Cell metabolism.

[40]  F. Maxfield,et al.  Role of cholesterol and lipid organization in disease , 2005, Nature.

[41]  G. Musso,et al.  Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.

[42]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.